XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating Activities    
Net income (loss) $ (3,788) $ 32,212
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Stock-based compensation expense 397 1,085
Depreciation and amortization 4 220
Change in fair value of long-term receivables (134)  
Change in fair value of derivative liabilities 134  
Bad debt expense   200
Loss on lease termination   110
Net gain on disposal of assets (4,736) (57,245)
Changes in operating assets and liabilities:    
Accounts and other receivables   1,618
Other receivables from GNI (1,200)  
Prepaid insurance (33)  
Prepaid and other current assets (131) 993
Accounts payable (36) (6,378)
Accrued compensation and other accrued liabilities (2,409) (4,317)
Operating lease liability and right-of-use asset 28 111
Deferred revenue   (230)
Net cash used in operating activities (11,904) (31,621)
Investing Activities    
Proceeds from maturities of short-term investments   2,504
Proceeds from the sale of property and equipment   447
Proceeds from the sale of complement portfolio to Vertex 5,000 55,000
Payment of transaction costs in connection with the sale of complement portfolio to Vertex   (2,576)
Proceeds from the sale of legacy rare bleeding disorder program to GCBP 1,000  
Payment of transaction costs in connection with the sale of legacy rare bleeding disorder program to GCBP (794)  
Net cash provided by investing activities 5,206 55,375
Financing Activities    
Payment of dividends (12,764) (45,031)
Issuance of common stock from stock grants and option exercises 24 20
Net cash used in financing activities (12,740) (45,011)
Net decrease in cash and cash equivalents (19,438) (21,257)
Cash and cash equivalents at beginning of the period 21,666 44,347
Cash and cash equivalents at end of the period 2,228 $ 23,090
Supplemental Disclosure on Non-Cash Investing and Financing Activities:    
CVR derivative liability $ 4,530